Interpace Biosciences, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.9M | $13.1M | $9.4M | $119.9M | $146.5M | $126.9M | $157.3M | $134.6M |
| Cost of Revenue | $7.4M | $6.6M | $6.9M | $1.3M | — | — | — | — |
| Gross Profit | $8.5M | $6.4M | $2.5M | $206.0K | $23.5M | $26.9M | $32.5M | $26.6M |
| Gross Margin | 53.7% | 49.2% | 26.7% | 0.2% | 16.0% | 21.2% | 20.6% | 19.7% |
| Operating Expenses | ||||||||
| Research & Development | $1.5M | $1.6M | $2.3M | $255.0K | — | — | — | — |
| SG&A Expense | $9.2M | $10.5M | $16.9M | $14.3M | — | — | — | — |
| Operating Income | $-6.3M | $-6.4M | $-40.4M | $-17.8M | $-1.4M | $-25.2M | $-4.7M | $-6.9M |
| Operating Margin | -39.6% | -49.2% | -428.4% | -14.9% | -1.0% | -19.9% | -3.0% | -5.1% |
| Interest Expense | $433.0K | $2.1M | $3.7M | $602.0K | $0 | — | — | — |
| Pretax Income | $-13.1M | $-8.6M | $-44.2M | $-18.5M | $-1.5M | $-25.3M | $-4.7M | $-6.8M |
| Income Tax Expense | $-395.0K | $-162.0K | $-13.1M | $-5.0M | $180.0K | $208.0K | $-939.0K | $392.0K |
| Net Income | $12.6M | $-22.0M | $-13.6M | $-16.8M | $-4.6M | $-25.5M | $-11.9M | $-6.8M |
| Net Margin | 79.0% | -168.2% | -144.4% | -14.0% | -3.1% | -20.1% | -7.6% | -5.1% |
| EPS (Basic) | $-1.99 | $-3.36 | $-2.44 | $-3.13 | $-0.01 | $-0.05 | $-0.02 | $-0.01 |
| EPS (Diluted) | $-1.99 | $-3.36 | $-2.44 | $-3.13 | $-0.01 | $-0.05 | $-0.02 | $-0.01 |
| Shares Outstanding (Basic) | 63.1M | 65.4M | 55.7M | 536.4M | 529.8M | 525.1M | 519.8M | 515.0M |
| Shares Outstanding (Diluted) | 63.1M | 65.4M | 55.7M | 536.4M | 529.8M | 525.1M | 519.8M | 515.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |